tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Schnitzler M | Diabetes mellitus after kidney transplantation in the United States. | 2003 | Am. J. Transplant. | pmid:14510709 |
| Donners MM et al. | Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. | 2005 | Am. J. Transplant. | pmid:15888024 |
| Woodward RS et al. | Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. | 2003 | Am. J. Transplant. | pmid:12752315 |
| Lemahieu W et al. | Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. | 2005 | Am. J. Transplant. | pmid:15888045 |
| Axelrod D et al. | Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. | 2005 | Am. J. Transplant. | pmid:15888050 |
| Reyes J et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). | 2005 | Am. J. Transplant. | pmid:15888051 |
| Djamali A et al. | Nox2 is a mediator of chronic CsA nephrotoxicity. | 2012 | Am. J. Transplant. | pmid:22568654 |
| Campbell PM et al. | Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. | 2007 | Am. J. Transplant. | pmid:17456201 |
| English RF et al. | Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. | 2002 | Am. J. Transplant. | pmid:12243498 |
| Kurtz J et al. | Lack of role for CsA-sensitive or Fas pathways in the tolerization of CD4 T cells via BMT and anti-CD40L. | 2003 | Am. J. Transplant. | pmid:12814472 |
| Egli A et al. | Renal failure five years after lung transplantation due to polyomavirus BK-associated nephropathy. | 2010 | Am. J. Transplant. | pmid:20840474 |
| Ricciardelli I et al. | Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy. | 2013 | Am. J. Transplant. | pmid:24266973 |
| McKenna G and Trotter JF | Does early (CNI) conversion lead to eternal (renal) salvation? | 2010 | Am. J. Transplant. | pmid:20928938 |
| Schold JD | The burden of proof in the design of early phase clinical trials. | 2013 | Am. J. Transplant. | pmid:23802723 |
| Chisholm-Burns MA et al. | Improving outcomes of renal transplant recipients with behavioral adherence contracts: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23819827 |
| Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
| Srinivas TR et al. | The noninferiority trial: don't don't do it. | 2010 | Am. J. Transplant. | pmid:21087412 |
| Kasahara M et al. | Living-donor liver transplantation for hepatoblastoma. | 2005 | Am. J. Transplant. | pmid:16095502 |
| Lemahieu WP et al. | Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095503 |
| Meier-Kriesche HU et al. | Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. | 2005 | Am. J. Transplant. | pmid:16095509 |
| Senior PA et al. | Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. | 2005 | Am. J. Transplant. | pmid:16095517 |
| RodrÃguez-Perálvarez M et al. | Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. | 2013 | Am. J. Transplant. | pmid:23621166 |
| Vanhove T et al. | Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. | 2017 | Am. J. Transplant. | pmid:28224698 |
| Vongwiwatana A et al. | Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. | 2004 | Am. J. Transplant. | pmid:14678043 |
| Filler G et al. | Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. | 2005 | Am. J. Transplant. | pmid:15996252 |
| Awadalla Y et al. | HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. | 2004 | Am. J. Transplant. | pmid:15367226 |
| Froud T et al. | Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. | 2005 | Am. J. Transplant. | pmid:15996257 |
| Borrows R et al. | Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. | 2006 | Am. J. Transplant. | pmid:16433766 |
| Shihab F et al. | Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. | 2017 | Am. J. Transplant. | pmid:28141897 |
| Kohnle M et al. | Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. | 2006 | Am. J. Transplant. | pmid:16433776 |
| O'Connell PJ et al. | Multicenter Australian trial of islet transplantation: improving accessibility and outcomes. | 2013 | Am. J. Transplant. | pmid:23668890 |
| Russ GR et al. | Efficacy of sotrastaurin plus tacrolimus after de novo kidney transplantation: randomized, phase II trial results. | 2013 | Am. J. Transplant. | pmid:23668931 |
| RodrÃguez-Perálvarez M et al. | Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. | 2012 | Am. J. Transplant. | pmid:22703529 |
| Guirado L et al. | Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21668633 |
| Flechner SM et al. | The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. | 2011 | Am. J. Transplant. | pmid:21668635 |
| Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
| Chen G et al. | Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. | 2007 | Am. J. Transplant. | pmid:17227555 |
| Senior PA et al. | Changes in renal function after clinical islet transplantation: four-year observational study. | 2007 | Am. J. Transplant. | pmid:17227560 |
| Asberg A et al. | Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. | 2010 | Am. J. Transplant. | pmid:20486914 |
| Hautz T et al. | Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. | 2010 | Am. J. Transplant. | pmid:20353468 |
| Zheng H et al. | Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. | 2003 | Am. J. Transplant. | pmid:12694072 |
| Montgomery SP et al. | Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. | 2002 | Am. J. Transplant. | pmid:12118862 |
| Ahsan N et al. | Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. | 2002 | Am. J. Transplant. | pmid:12118902 |
| Nijhoff MF et al. | Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. | 2016 | Am. J. Transplant. | pmid:26288226 |
| Lefaucheur C et al. | Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. | 2008 | Am. J. Transplant. | pmid:18671673 |
| McDonald RA et al. | Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. | 2008 | Am. J. Transplant. | pmid:18416737 |
| Triñanes J et al. | Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Cells. | 2017 | Am. J. Transplant. | pmid:28432716 |
| Pallet N et al. | Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. | 2016 | Am. J. Transplant. | pmid:26990694 |
| Rogers J et al. | Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. | 2003 | Am. J. Transplant. | pmid:14510702 |
| Chhabra D et al. | Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. | 2013 | Am. J. Transplant. | pmid:24007570 |